ABSTRACT
Transforming growth factor (TGF)-ß1 and prostaglandin E2 (PGE2) are humoral factors critically involved in the induction of immunosuppression in the microenvironment of various types of tumors, including melanoma. In this study, we identified a natural compound that attenuated TGF-ß1- and PGE2-induced immunosuppression and examined its effect on B16 melanoma growth in mice. By screening 502 natural compounds for attenuating activity against TGF-ß1- or PGE2-induced suppression of cytolysis in poly(I:C)-stimulated murine splenocytes, we found that betulin was the most potent compound. Betulin also reduced TGF-ß1- and PGE2-induced downregulation of perforin and granzyme B mRNA expression and cell surface expression of NKG2D and CD69 in natural killer (NK) cells. Cell depletion and coculture experiments showed that NK cells, dendritic cells, B cells, and T cells were necessary for the attenuating effects of betulin. Structure-activity relationship analysis revealed that two hydroxyl groups at positions C3 and C28 of betulin, their cis-configuration, and methyl group at C30 played crucial roles in its attenuating activity. In a subcutaneous implantation model of B16 melanoma in mice, intratumor administration of betulin and LY2157299, a TGF-ß1 type I receptor kinase inhibitor, significantly retarded the growth of B16 melanoma. Notably, betulin increased significantly the number of CD69 positive NK cells in tumor sites at early stages of post-tumor cell injection. Our data suggest that betulin inhibits the growth of B16 melanoma by enhancing NK cell activity through attenuating the immunosuppressive tumor microenvironment.
Subject(s)
Dinoprostone , Melanoma, Experimental , Transforming Growth Factor beta1 , Triterpenes , Animals , Dinoprostone/metabolism , Killer Cells, Natural , Melanoma, Experimental/drug therapy , Melanoma, Experimental/metabolism , Mice , Transforming Growth Factor beta1/metabolism , Triterpenes/pharmacology , Tumor MicroenvironmentABSTRACT
The Toll-like receptor 4 (TLR4)/myeloid differentiation factor-2 (MD-2) complex is essential for LPS recognition and induces innate immune responses against Gram-negative bacteria. As activation of TLR4/MD-2 is also critical for the induction of adaptive immune responses, TLR4/MD-2 agonists have been developed as vaccine adjuvants, but their efficacy has not yet been ascertained. Here, we demonstrate that a funiculosin (FNC) variant, FNC-RED, and FNC-RED and FNC derivatives are agonists for both murine and human TLR4/MD-2. FNC-RED induced nuclear factor-κB (NF-κB) activation via murine TLR4/MD-2, whereas FNC had no TLR4/MD-2 stimulatory activity. Biacore analysis revealed that FNC-RED binds to murine TLR4/MD-2 but not murine radioprotective 105 (RP105)/myeloid differentiation factor-1 (MD-1), another LPS sensor. FNC-RED induced CD14-independent expressions of pro-inflammatory cytokines and co-stimulatory molecules in murine macrophages and dendritic cells. In contrast, FNC-RED stimulation was reduced in CD14-dependent LPS responses, including dimerization and internalization of TLR4/MD-2 and IFN-ß expression. FNC-RED-induced IL-12p40 production from murine dendritic cells was dependent on NF-κB but not MAPK pathway. In addition, fetal bovine serum augmented lipid A-induced NF-κB activation but blocked FNC-RED-mediated responses. Two synthetic phosphate group-containing FNC-RED and FNC derivatives, FNC-RED-P01 and FNC-P01, respectively, activated human TLR4/MD-2, unlike FNC-RED. Finally, computational analysis revealed that this species-specific activation by FNC-RED and FNC-RED-P01 resulted from differences in electrostatic surface potentials between murine and human TLR4/MD-2. We conclude that FNC-RED and its synthetic derivative represent a novel category of murine and human TLR4/MD-2 agonist.
Subject(s)
Dendritic Cells/drug effects , Immunity, Innate/drug effects , Lymphocyte Antigen 96/agonists , Macrophages/drug effects , Models, Immunological , Toll-Like Receptor 4/agonists , Animals , Binding Sites , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , Cell Line , Cells, Cultured , Computational Biology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Drug Design , Humans , Ligands , Lymphocyte Antigen 96/chemistry , Lymphocyte Antigen 96/genetics , Lymphocyte Antigen 96/metabolism , Macrophages/cytology , Macrophages/immunology , Macrophages/metabolism , Mice, Inbred C57BL , Mice, Knockout , Molecular Docking Simulation , Phosphorylation , Pyridones/chemistry , Pyridones/pharmacology , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Specific Pathogen-Free Organisms , Structure-Activity Relationship , Toll-Like Receptor 4/chemistry , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolismABSTRACT
The present study was conducted to determine whether cutaneous itch involves mu-opioid receptors in either of the spinal cord or lower brainstem or in both regions in mice. An intraplantar injection of serotonin hydrochloride (100 nmol/site) induced biting, an itch-related behavior. The behavior was inhibited by subcutaneous (0.3-1 mg/kg) and intracisternal (1--10 nmol/site), but not intrathecal (1--10 nmol/site), injections of naloxone hydrochloride. An intradermal injection of serotonin (100 nmol/site) to the rostral back induced scratching, an itch-related behavior, which was inhibited by subcutaneous (1 mg/kg) and intracisternal (10 nmol/site) injections of naloxone. These results suggest that mu-opioid receptor in the lower brainstem, but not spinal cord, is a site of central pruritogenic action of opioids and is involved in the facilitatory regulation of itch signaling.
Subject(s)
Behavior, Animal/drug effects , Cisterna Magna/metabolism , Naloxone , Narcotic Antagonists , Pruritus/drug therapy , Animals , Brain Stem/drug effects , Brain Stem/metabolism , Cisterna Magna/drug effects , Injections, Spinal , Injections, Subcutaneous , Ligands , Male , Mice , Mice, Inbred ICR , Naloxone/administration & dosage , Naloxone/pharmacology , Naloxone/therapeutic use , Narcotic Antagonists/administration & dosage , Narcotic Antagonists/pharmacology , Narcotic Antagonists/therapeutic use , Pruritus/metabolism , Receptors, Opioid, mu/metabolism , Serotonin/pharmacology , Spinal Cord/drug effects , Spinal Cord/metabolismABSTRACT
The common adverse effect of centrally-injected mu-opioid receptor (mu-OR) agonists is pruritus. This study was conducted using mice to examine whether different subtypes of mu-OR would be responsible for pruritus and analgesia. Intracisternal injections of morphine and morphine-6beta-glucronide (M6G), but not M3G, produced an antinociceptive effect. Morphine, but neither M6G nor M3G, induced facial scratching, a pruritus-related response. Facial scratching following morphine was not affected by the mu(1)-OR antagonist naloxonazine at doses that inhibited the antinociceptive effects. The results suggest that different subtype and/or splice variants of mu-OR are separately involved in pruritus and antinociception of opioids.
Subject(s)
Analgesics, Opioid/administration & dosage , Behavior, Animal/drug effects , Morphine/administration & dosage , Pain Threshold/drug effects , Pruritus/chemically induced , Receptors, Opioid, mu/agonists , Analgesics, Opioid/toxicity , Animals , Dose-Response Relationship, Drug , Injections, Subcutaneous , Male , Mice , Mice, Inbred ICR , Morphine/toxicity , Morphine Derivatives/administration & dosage , Naloxone/administration & dosage , Naloxone/analogs & derivatives , Narcotic Antagonists/administration & dosage , Pain Measurement , Pruritus/metabolism , Pruritus/prevention & control , Receptors, Opioid, mu/metabolism , Time FactorsABSTRACT
Thromboxane A2 (TXA2), a metabolite of arachidonic acid produced by cyclooxygenase and thromboxane synthase, is thought to participate in chronic dermatitis. This study investigated the involvement of TXA2 in cutaneous itch. An intradermal injection of U-46619, a stable analogue of TXA2, elicited scratching, an itch-associated response, in mice. Dose-response curve was bell shaped with a maximum effect at 10 nmol per site. The action of U-46619 was inhibited by a coinjection of the TP antagonist ONO-3708 and was abolished by TP receptor deficiency. TP receptor was mainly expressed in nerve fiber in the skin and keratinocytes. Thromboxane synthase was also expressed in keratinocytes. U-46619 increased intracellular Ca2+ ion concentration in primary cultures of dorsal root ganglion neurons and keratinocytes. The results suggest that TXA2 synthesized by keratinocytes acts as an itch mediator. It may elicit itch through the activation of TP receptors on primary afferents and keratinocytes; keratinocytes may produce itch mediators including TXA2. Thus, thromboxane synthase inhibitor and TP receptor antagonists will be candidates for antipruritic medicines.
Subject(s)
Pruritus/etiology , Receptors, Thromboxane/physiology , Thromboxane A2/physiology , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Animals , Ganglia, Spinal/drug effects , Keratinocytes/drug effects , Male , Mast Cells/physiology , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Receptors, Thromboxane/analysis , Thromboxane-A Synthase/analysisABSTRACT
To find new antipruritic herbal medicines for pruritus, we screened the methanol extracts of seven herbal medicines which have been used to treat dermatologic diseases, testing them on mouse models of acute and chronic itch. When administrated perorally (p.o.) at a dose of 200 mg/kg, methanol extracts of Sophora flavescens and Cnidium monnieri, but not the others, significantly inhibited a serotonin (5-HT)-induced itch-related response (scratching) and the spontaneous scratching of NC mice, a mouse model of atopic dermatitis. The inhibitory effect of Sophora flavescens was stronger than that of Cnidium monnieri. The methanol extract from Sophora flavescens (50-200 mg/kg) inhibited 5-HT-induced scratching in a dose-dependent manner, without any effects on the locomotor activity. These results suggest that Sophora flavescens and its constituents widely affect acute and chronic pruritus, and are possible as new antipruritic agents.
Subject(s)
Antipruritics/therapeutic use , Phytotherapy , Pruritus/drug therapy , Sophora/chemistry , Acute Disease , Administration, Oral , Animals , Antipruritics/administration & dosage , Behavior, Animal , Chronic Disease , Disease Models, Animal , Male , Mice , Mice, Inbred ICR , Motor Activity/drug effects , Plant Extracts/pharmacologyABSTRACT
The effects of the opioid antagonist naltrexone on spontaneous itch-associated behaviors and cutaneous nerve activities were examined to determine whether it inhibits pruritus through peripheral action in NC mice with chronic dermatitis. Their rostral-back scratching and caudal-back biting were 19 and 3.4 times more, respectively, than those of control mice. The activities of cutaneous nerves innervating the rostral and caudal back were 9.5 and 5.4 times more, respectively, in affected mice than in control mice. Subcutaneous injections of naltrexone significantly inhibited the scratching and biting, without effects on the nerve activities. The results suggest that the peripheral action does not play a central role in inhibiting chronic itch-associated behaviors.